Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS: Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Not reported 1 (1) 1 (3) 1 (1) 1 (2) 2 (1)”
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“>ULN 15 (21) 7 (19) 24 (25) 11 (23) 35 (25)”
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 3×
“Stable disease 9 (12) 13 (35) 3 (13) 1 (10)”
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“M1b 22 (31) 8 (22) 27 (28) 12 (26) 39 (27)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 4×
“Increased lipase 12 (13) 8 (9) 2 (4) 1 (2)”
InfluentialSelf-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citation
Cited by
Items 701–800 of 1,008
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000503254 · Cited by 70
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13081 · Cited by 70
Saha, D., Wakimoto, H., Peters, C. W., Antoszczyk, S. J., Rabkin, S. D., & Martuza, R. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1717 · Cited by 72
Perrinjaquet, C., Desbaillets, N., & Hottinger, A. F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000686 · Cited by 78
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Lemiale, V., Meert, A., Vincent, F., Darmon, M., Bauer, P. R., de Louw, A. V., & Azoulay, É. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0487-x · Cited by 90
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 82
“28 No validated predictive biomarkers to identify the patients who will benefit from ICIs were available for routine clinical use at the time of guideline publication.”
BackgroundSelf-citationDeutsch, G. B., Flaherty, D. C., Kirchoff, D. D., Bailey, M., Vitug, S., Foshag, L. J., Faries, M. B., & Bilchik, A. J. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.0459 · Cited by 77
Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017) · Tumori Journal · doi:10.5301/tj.5000625 · Cited by 72
The role of tumor microenvironment in resistance to anti-angiogenic therapy
Ma, S., Pradeep, S., Hu, W., Zhang, D., Coleman, R. L., & Sood, A. K. (2018) · F1000Research · doi:10.12688/f1000research.11771.1 · Cited by 76
Tallerico, R., Cristiani, C. M., Staaf, E., Garofalo, C., Sottile, R., Capone, M., de Coaña, Y. P., Madonna, G., Palella, E., Wolodarski, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1261242 · Cited by 74
Checkpoint Blockade in Lung Cancer and Mesothelioma
Lievense, L. A., Sterman, D. H., Cornelissen, R., & Aerts, J. G. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1755ci · Cited by 69
Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
Karlsson, A., & Saleh, S. N. (2017) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s120877 · Cited by 79
A Blueprint to Advance Colorectal Cancer Immunotherapies
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A., Marsilje, T. H., Brodsky, A. N., Chan, E., Deming, D. A., Diaz, L. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0375 · Cited by 69
Fujisawa, Y., Yoshino, K., Otsuka, A., Funakoshi, T., Uchi, H., Fujimura, T., Matsushita, S., Hata, H., Okuhira, H., Tanaka, R., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.10.009 · Cited by 73
Kidney Complications of Immune Checkpoint Inhibitors: A Review
Shingarev, R. A., & Glezerman, I. G. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.03.433 · Cited by 76
“Such severe adverse effects include pneumonitis and primary adrenal insufficiency and require prompt recognition and treatment.(35, 36)”
BackgroundChyuan, I., Chu, C., & Hsu, P. (2021) · Cancers · doi:10.3390/cancers13061188 · Cited by 71
Bell, R. B., Leidner, R. S., Crittenden, M. R., Curti, B. D., Feng, Z., Montler, R. D., Gough, M. J., Fox, B. A., Weinberg, A. D., & Urba, W. J. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.009 · Cited by 73
An, Y., Jiang, W., Kim, B. Y. S., Qian, J. M., Tang, C. Z., Fang, P., Logan, J. K., D’Souza, N. M., Haydu, L. E., Wang, X. A., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.08.009 · Cited by 69
Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies
Noble, C. W., Gangaputra, S. S., Thompson, I., Yuan, A., Apolo, A. B., Lee, J., Papaliodis, G. N., Kodati, S., Bishop, R. J., Magone, M. T., et al. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1583347 · Cited by 70
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2016) · Liver Cancer · doi:10.1159/000449342 · Cited by 70
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Haines, B. B., Denslow, A., Grzesik, P., Lee, J. S., Farkaly, T., Hewett, J., Wambua, D., Kong, L., Behera, P., Jacques, J., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0609 · Cited by 73
“However, systemic administration as a monotherapy or in combination is associated with immune-mediated adverse events that can be severe (46, 47).”
Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis
Hutchinson, J. A., Kronenberg, K., Riquelme, P., Wenzel, J. J., Glehr, G., Schilling, H., Zeman, F., Evert, K., Schmiedel, M., Mickler, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21572-y · Cited by 72
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.09.002 · Cited by 75
Allen, C. T., Clavijo, P. E., Waes, C. V., & Chen, Z. (2015) · Cancers · doi:10.3390/cancers7040900 · Cited by 74
Wang, S., Li, H., Li, B., Xie, T., Zhu, T., Sun, L., Ren, H., & Ye, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.016 · Cited by 70
Shurell, E., Singh, A. S., Crompton, J. G., Jensen, S. L., Li, Y., Dry, S., Nelson, S. D., Chmielowski, B., Bernthal, N. M., Federman, N. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11734 · Cited by 82
Drug-Related Pneumonitis in the Era of Precision Cancer Therapy
Nishino, M., Hatabu, H., Hodi, F. S., & Ramaiya, N. H. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00026 · Cited by 74
Self-citationStrategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 67
Current status of immunotherapy
Suzuki, S., Ishida, T., Yoshikawa, K., & Ueda, R. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv201 · Cited by 71
Immune Mechanisms in Myelodysplastic Syndrome
Glenthøj, A. B., Ørskov, A. D., Hansen, J., Hadrup, S. R., O'Connell, C. L., & Grønbæk, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060944 · Cited by 76
PD-1 checkpoint inhibition: Toxicities and management
Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.005 · Cited by 73
Design considerations for early-phase clinical trials of immune-oncology agents
Wages, N. A., Chiuzan, C. C., & Panageas, K. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0389-8 · Cited by 69
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 78
Agostinetto, E., Eiger, D., Lambertini, M., Ceppi, M., Bruzzone, M., Ponde, N. F., Plummer, C., Awada, A. H., Santoro, A., Piccart, M. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.043 · Cited by 70
Campana, L. G., Perić, B., Mascherini, M., Spina, R., Kunte, C., Kis, E. G., Rózsa, P., Quaglino, P., Jones, R. P., Clover, A. J. P., et al. (2021) · Cancers · doi:10.3390/cancers13174289 · Cited by 79
“There is a lack of solid data about the effectiveness of immunotherapy on cutaneous metastases, likely due to the scarce representation of patients with stage III in-transit and stage IV–M1a disease in the major randomized trials [35].”
BackgroundWang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
“More recent trials have shown superior anti-tumor efficacy with the dual combination of CTLA-4 and PD-1 blockade in melanoma, suggesting concurrent administration may be a beneficial therapeutic strategy; although with increased risk of toxicities (11, 78, 79).”
BackgroundExposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 68
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 72
The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases
Sperduto, P. W., Jiang, W., Brown, P. D., Braunstein, S. E., Sneed, P. K., Wattson, D. A., Shih, H. A., Bangdiwala, A. S., Shanley, R., Lockney, N. A., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.03.030 · Cited by 66
Melanoma and Immune Checkpoint Inhibitors
Furue, M., Ito, T., Wada, N. A., Wada, M., Kadono, T., & Uchi, H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0676-z · Cited by 71
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000496277 · Cited by 69
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2873-x · Cited by 64
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000501501 · Cited by 71
Potential Successes and Challenges of Targeted Cancer Therapies
Keefe, D. M. K., & Bateman, E. H. (2019) · JNCI Monographs · doi:10.1093/jncimonographs/lgz008 · Cited by 64
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Aziz, M. A. A. E., Facciorusso, A., Nayfeh, T., Saadi, S. M., Elnaggar, M. Y., Cotsoglou, C., & Sacco, R. (2020) · Vaccines · doi:10.3390/vaccines8040616 · Cited by 67
“The success achieved in these trials especially in for patients with melanoma [36] has inspired the application of dual immune blockage for other types of cancers including HCC.”
BackgroundCombining nanomedicine and immune checkpoint therapy for cancer immunotherapy
Boone, C. E., Wang, L., Gautam, A., Newton, I. G., & Steinmetz, N. F. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1739 · Cited by 76
(Neo)adjuvant systemic therapy for melanoma
van Zeijl, M. C. T., van den Eertwegh, A. J. M., Haanen, J. B. A. G., & Wouters, M. W. J. M. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.001 · Cited by 65
Alvarez-Breckenridge, C. A., Giobbie‐Hurder, A., Gill, C. M., Bertalan, M. S., Stocking, J. H., Kaplan, A. B., Nayyar, N., Lawrence, D. P., Flaherty, K. T., Shih, H. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0306 · Cited by 80
Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy
Sobol, I., Chen, C. L., Mahmood, S., & Borczuk, A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0447-oa · Cited by 71
MCFF-MTDDI: multi-channel feature fusion for multi-typed drug–drug interaction prediction
Han, C., Wang, C.-C., Huang, L., & Chen, X. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad215 · Cited by 68
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 90
“Apositivepredictivemarker is considered to be the PD-L1 expression on tumor cells 13,19,20 , although many patients do not respond to ICI treatment despite having tumors with high PD-L1 expression 21 .”
BackgroundSherafat, N. S., Keshavarz, A., Mardi, A., Mohammadiara, A., Aghaei, M., Maleki, L. A., & Mohammadi, M. H. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01751-7 · Cited by 69
“T cells undergo metabolic changes as a result of PD-1 signaling, which increases fatty acid oxidation while decreasing glycolysis [176].”
Devji, T., Levine, O. H., Neupane, B., Beyene, J., & Xie, F. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4877 · Cited by 70
Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000122 · Cited by 70
Martini, D. J., Hamieh, L., McKay, R. R., Harshman, L. C., Moreira, R. B., Norton, C. K., Steinharter, J. A., Krajewski, K. M., Gao, X. Y., Schutz, F. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0220 · Cited by 65
Self-citationSevere neurologic complications of immune checkpoint inhibitors: a single-center review
Mancone, S. E., Lycan, T. W., Ahmed, T., Topaloĝlu, Ü., Dothard, A., Petty, W. J., & Strowd, R. E., III (2018) · Journal of Neurology · doi:10.1007/s00415-018-8890-z · Cited by 72
New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
Ciccarese, C., Alfieri, S., Santoni, M., Santini, D., Brunelli, M., Bergamini, C., Licitra, L. F., Montironi, R., Tortora, G., & Massari, F. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1120287 · Cited by 68
Neopterin as a biomarker of immune response in cancer patients
Melichar, B., Spisarová, M., Bartoušková, M., Krčmová, L. K., Javorská, L., & Študentová, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.29 · Cited by 69
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
Sadozai, H., Gruber, T., Hunger, R. E., & Schenk, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01617 · Cited by 67
Owen, D. H., Chu, B. F., Lehman, A. M., Annamalai, L., Yearley, J. H., Shilo, K., & Otterson, G. A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.013 · Cited by 71
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Yusko, E. C., Vignali, M., Wilson, R. K., Mardis, E. R., Hodi, F. S., Horak, C. E., Chang, H., Woods, D. M., Robins, H. S., & Weber, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0226 · Cited by 63
Self-citationRecent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Balaji, A., Zhang, J., Wills, B., Marrone, K. A., Elmariah, H., Yarchoan, M. M., Zimmerman, J. W., Hajjir, K., Venkatraman, D., Armstrong, D. K., et al. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00703 · Cited by 68
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 66
Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy
Baniyash, M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1849-y · Cited by 62
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 67
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry
Martínez-Morilla, S., Villarroel‐Espíndola, F., Wong, P. F., Toki, M. I., Aung, T. N., Pelekanou, V., Bourke-Martin, B., Schalper, K. A., Kluger, H. M., & Rimm, D. L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3340 · Cited by 65
“Even though patients frequently respond to these drugs, reaching up to 60% with the combined therapy (6), there are still patients that do not benefit or develop adverse events related to immune resistance (1–4).”
BackgroundKovacs, S., & Győrffy, B. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03409-4 · Cited by 67
“In the last 10 years, further indications were approved in different subsets of melanoma either as a monotherapy or as a combination therapy with nivolumab, like in B-Raf Proto-Oncogene (BRAF) V600 wild-type unresectable or metastatic melanoma [10].”
BackgroundAzpilikueta, A., Agorreta, J., Labiano, S., Perez‐Gracia, J. L., Sánchez-Paulete, A. R., Aznar, M. A., Ajona, D., Bazo, I. G., Larráyoz, M., Teijeira, Á., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.013 · Cited by 64
Amin, A., Lawson, D. H., Salama, A. K. S., Koon, H. B., Guthrie, T. H., Thomas, S. S., O'Day, S. J., Shaheen, M. F., Zhang, B., Francis, S., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0148-7 · Cited by 68
Self-citationAdverse Events in Cancer Immunotherapy
Abdel‐Wahab, N., Alshawa, A., & Suarez-Almazor, M. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_8 · Cited by 70
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 70
Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma
Vennepureddy, A., Thumallapally, N., Nehru, V. M., Atallah, J. P., & Terjanian, T. O. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2424w · Cited by 67
Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis
Pasquali, S., Chiarion‐Sileni, V., Rossi, C. R., & Mocellin, S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.006 · Cited by 64
Ma, X., Zhang, Y., Wang, S., Wei, H., & Yu, J. (2021) · Journal of Cancer · doi:10.7150/jca.49174 · Cited by 63
“After excluding articles that did not meet the requirements, the full text of the remaining 26 articles was then reviewed, and 10 studies (15 cohorts) [5,6,7,8,9,10,11,12,13,14] involving 2410 patients were finally included in the meta-analysis.”
BackgroundBashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
“better response rates and reduced tumor burden compared to the monotherapy of each drug (Postow et al., 2015).”
BackgroundThyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 68
Cortellino, S., Quagliariello, V., Delfanti, G., Blaževitš, O., Chiodoni, C., Maurea, N., Mauro, A. D., Tatangelo, F., Pisati, F., Shmahala, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41066-3 · Cited by 73
Reddy, S. M., Reuben, A., & Wargo, J. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0531-z · Cited by 63
PD-L1 Expression in Pancreatic Cancer
Zheng, L. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw304 · Cited by 64
Experimental animal modeling for immuno-oncology
Li, Q., Feuer, G., Ouyang, X., & An, X. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.002 · Cited by 67
Bello, D. M., Panageas, K. S., Hollmann, T. J., Shoushtari, A. N., Momtaz, P., Chapman, P. B., Postow, M. A., Callahan, M. K., Wolchok, J. D., Brady, M. S., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08099-9 · Cited by 62
Self-citationCytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
Mohammad, G. R. K. S., Ghahremanloo, A., Soltani, A., Fathi, E., & Hashemy, S. I. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29491 · Cited by 66
“For this purpose, several studies were conducted about the combination of anti‐PD‐1/PDL‐1 antibodies with other immune‐modulating factors or chemical agents that appears to be more effective than monotherapy (Larkin et al., 2015; Postow et al., 2015; West et al., 2013; Wolchok et al., 2013).”
BackgroundFormate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
Rowe, J. H., Elia, I., Shahid, O., Gaudiano, E. F., Sifnugel, N. E., Johnson, S., Reynolds, A. G., Fung, M. E., Joshi, S., LaFleur, M. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1301 · Cited by 59
Immune checkpoint inhibitors in older adults
Elias, R., Morales, J., Rehman, Y., & Khurshid, H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0534-9 · Cited by 59
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Carlino, M. S., & Long, G. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2944 · Cited by 59
First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation
Bodor, J. N., Kasireddy, V., & Borghaei, H. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00250 · Cited by 66
Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma
Mason, R., Dearden, H. C., Nguyen, B., Soon, J. A., Smith, J. L., Randhawa, M., Mant, A. M., Warburton, L., Lo, S., Meniawy, T. M., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12831 · Cited by 64
“…over PD‐1 monotherapy (noting that the trial was powered for a comparison between nivolumab containing arms and ipilimumab only) (Larkin et al., 2015; Postow et al., 2015; Wolchok et al., 2017), and one recent clinical trial has demonstrated a higher response rate and superior progression‐free…”
BackgroundInfluentialVISTA expression and patient selection for immune-based anticancer therapy
Martin, A. S., Molloy, M., Ugolkov, A. V., Roemeling, R. W. V., Noelle, R. J., Lewis, L. D., Johnson, M. L., Radvanyi, L. G., & Martell, R. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086102 · Cited by 64
Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care
Ben-Aharon, O., Magnezi, R., Leshno, M., & Goldstein, D. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4445 · Cited by 60
Nivolumab in Nonsquamous Non–Small-Cell Lung Cancer
Hasegawa, T., Uno, H., & Wei, L.-J. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1514790 · Cited by 59
Hercun, J., Vincent, C., Bilodeau, M., & Lapierre, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907591 · Cited by 64
Park, H.-R., Shiva, A., Cummings, P., Kim, S., Kim, S., Lee, E., Leong, A., Chowdhury, S., Shawber, C. J., Carvajal, R. D., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2838 · Cited by 67
Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients
Lee, A. Y., Nicolás Droppelmann, M., Panageas, K. S., Zhou, Q. C., Ariyan, C. E., Brady, M. S., Chapman, P. B., & Coit, D. G. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5642-0 · Cited by 58
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
Dutoit, V., Migliorini, D., Dietrich, P., & Walker, P. R. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00256 · Cited by 66
Garcia-Neuer, M. I., Marmarelis, M. E., Jangi, S., Luke, J. J., Ibrahim, N., Davis, M., Weinberg, J., Donahue, H., Bailey, N., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0302 · Cited by 59
Self-citationRheumatologic symptoms in oncologic patients on PD-1 inhibitors
Kuswanto, W. F., MacFarlane, L. A., Gedmintas, L., Mulloy, A., Choueiri, T. K., & Bermas, B. L. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.10.018 · Cited by 59
Zhou, S., Khanal, S., & Zhang, H. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s193338 · Cited by 58
Metadata
- Authors
- Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D., & Hodi, F. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Université Paris-Sud (FR)
- Beth Israel Deaconess Medical Center (US)
- From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) — all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) — all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D....
- Prisma Health (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-21
- Volume
- 372
- Issue
- 21
- Pages
- 2006-2017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5744258
- OpenAlex
- W2128758225
- Cited by
- 2,781
- References
- 28
- Citations by year
- 2026: 53 · 2025: 91 · 2024: 131 · 2023: 175 · 2022: 174 · 2021: 206 · 2020: 261 · 2019: 277 · 2018: 372 · 2017: 449 · 2016: 402 · 2015: 183
- FWCI
- 204.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, metastatic melanoma, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, objective response rate, progression-free survival, BRAF V600 mutation, immune-related adverse events, first-line therapy, dose escalation, complete response, duration of response
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Disease-Free Survival, Tumor Burden, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.